骨髓增殖性肿瘤中的微环境。
The Microenvironment in Myeloproliferative Neoplasms.
机构信息
Division of Hematology/Oncology, Department of Medicine, University of California, 839 Health Sciences Road, Sprague Hall B100, Irvine, CA 92617, USA.
Division of Hematology/Oncology, Department of Medicine, University of California, 839 Health Sciences Road, Sprague Hall B100, Irvine, CA 92617, USA; Department of Biological Chemistry, Irvine Chao Family Comprehensive Cancer Center, University of California, 839 Health Sciences Road, Sprague Hall 126, Irvine, CA 92617, USA.
出版信息
Hematol Oncol Clin North Am. 2021 Apr;35(2):205-216. doi: 10.1016/j.hoc.2020.11.003. Epub 2020 Dec 9.
Abstract
Chronic inflammation is a hallmark of myeloproliferative neoplasms (MPNs), with elevated levels of proinflammatory cytokines being commonly found in all 3 subtypes. Systemic inflammation is responsible for the constitutional symptoms, thrombosis risk, premature atherosclerosis, and disease evolution in MPN. Although the neoplastic clone and their differentiated progeny drive the inflammatory process, they also induce ancillary cytokine secretion from nonmalignant cells. Here, the authors describe the inflammatory milieu in MPN based on soluble factors and cellular mediators. They also discuss the prognostic value of cytokine measurements in patients with MPN and potential therapeutic strategies that target the cellular players in inflammation.
摘要
慢性炎症是骨髓增殖性肿瘤（MPNs）的一个标志，所有 3 种亚型中通常都存在高水平的促炎细胞因子。全身炎症是导致 MPN 患者出现全身症状、血栓形成风险、早发动脉粥样硬化和疾病进展的原因。虽然肿瘤克隆及其分化后代驱动炎症过程，但它们也会诱导非恶性细胞分泌辅助性细胞因子。在这里，作者根据可溶性因子和细胞介质描述了 MPN 中的炎症环境。他们还讨论了细胞因子测量在 MPN 患者中的预后价值和针对炎症中细胞成分的潜在治疗策略。
相似文献
1
The Microenvironment in Myeloproliferative Neoplasms.骨髓增殖性肿瘤中的微环境。
Hematol Oncol Clin North Am. 2021 Apr;35(2):205-216. doi: 10.1016/j.hoc.2020.11.003. Epub 2020 Dec 9.
2
Inflammation and myeloproliferative neoplasms.炎症和骨髓增殖性肿瘤。
J Autoimmun. 2017 Dec;85:58-63. doi: 10.1016/j.jaut.2017.06.010. Epub 2017 Jun 30.
3
Cytokine Regulation of Microenvironmental Cells in Myeloproliferative Neoplasms.骨髓增殖性肿瘤中微环境细胞的细胞因子调节
Mediators Inflamm. 2015;2015:869242. doi: 10.1155/2015/869242. Epub 2015 Oct 12.
4
Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both.骨髓增殖性肿瘤与炎症：靶向恶性克隆还是炎症过程，或者两者兼而有之。
Leukemia. 2016 May;30(5):1018-24. doi: 10.1038/leu.2016.12. Epub 2016 Feb 8.
5
The pathobiology of thrombosis, microvascular disease, and hemorrhage in the myeloproliferative neoplasms.骨髓增殖性肿瘤中的血栓形成、微血管病和出血的病理生物学。
Blood. 2021 Apr 22;137(16):2152-2160. doi: 10.1182/blood.2020008109.
6
JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.恶性和非恶性细胞中的JAK-STAT信号通路激活有助于骨髓增殖性肿瘤的发病机制和治疗反应。
Cancer Discov. 2015 Mar;5(3):316-31. doi: 10.1158/2159-8290.CD-14-0736. Epub 2015 Jan 8.
7
Fecal Microbial Community Composition in Myeloproliferative Neoplasm Patients Is Associated with an Inflammatory State.骨髓增殖性肿瘤患者的粪便微生物群落组成与炎症状态有关。
Microbiol Spectr. 2022 Jun 29;10(3):e0003222. doi: 10.1128/spectrum.00032-22. Epub 2022 Apr 27.
8
Inflammation as a Driver of Clonal Evolution in Myeloproliferative Neoplasm.炎症作为骨髓增殖性肿瘤克隆进化的驱动因素
Mediators Inflamm. 2015;2015:606819. doi: 10.1155/2015/606819. Epub 2015 Oct 11.
9
Platelets as Mediators of Thromboinflammation in Chronic Myeloproliferative Neoplasms.血小板在慢性骨髓增殖性肿瘤中的血栓炎症中介作用。
Front Immunol. 2019 Jun 14;10:1373. doi: 10.3389/fimmu.2019.01373. eCollection 2019.
10
Myeloproliferative neoplasm stem cells.骨髓增殖性肿瘤干细胞
Blood. 2017 Mar 23;129(12):1607-1616. doi: 10.1182/blood-2016-10-696005. Epub 2017 Feb 3.
引用本文的文献
1
Investigational drugs in early phase trials for myelofibrosis.用于骨髓纤维化早期试验的研究性药物。
Expert Opin Investig Drugs. 2024 Dec;33(12):1231-1244. doi: 10.1080/13543784.2024.2434696. Epub 2024 Nov 27.
2
Prevention and treatment of transformation of myeloproliferative neoplasms to acute myeloid leukemia.骨髓增殖性肿瘤转化为急性髓系白血病的防治
Haematologica. 2025 Apr 1;110(4):828-839. doi: 10.3324/haematol.2023.283950. Epub 2024 Oct 24.
3
Associations of the circulating levels of cytokines with the risk of myeloproliferative neoplasms: a bidirectional mendelian-randomization study.细胞因子循环水平与骨髓增殖性肿瘤风险的关联：一项双向孟德尔随机化研究
BMC Cancer. 2024 Apr 26;24(1):531. doi: 10.1186/s12885-024-12301-x.
4
Myeloproliferative Neoplasms: Contemporary Review and Molecular Landscape.骨髓增殖性肿瘤：当代综述与分子图谱
Int J Mol Sci. 2023 Dec 12;24(24):17383. doi: 10.3390/ijms242417383.
5
Putative Role of Neutrophil Extracellular Trap Formation in Chronic Myeloproliferative Neoplasms.中性粒细胞胞外诱捕网形成在慢性骨髓增殖性肿瘤中的推测作用。
Int J Mol Sci. 2023 Feb 24;24(5):4497. doi: 10.3390/ijms24054497.
6
Deepening Our Understanding of the Factors Affecting Landscape of Myeloproliferative Neoplasms: What Do We Know about Them?深化我们对影响骨髓增殖性肿瘤格局因素的理解：我们对它们了解多少？
Cancers (Basel). 2023 Feb 20;15(4):1348. doi: 10.3390/cancers15041348.
7
Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms.干扰素-α2 治疗真性红细胞增多症和相关肿瘤患者，有利于调节氧化应激基因和抗氧化防御机制的失调。
PLoS One. 2022 Jun 30;17(6):e0270669. doi: 10.1371/journal.pone.0270669. eCollection 2022.
8
Understanding Aberrant Signaling to Elude Therapy Escape Mechanisms in Myeloproliferative Neoplasms.了解异常信号传导以规避骨髓增殖性肿瘤中的治疗逃逸机制。
Cancers (Basel). 2022 Feb 15;14(4):972. doi: 10.3390/cancers14040972.
9
JAK2 inhibitor persistence in MPN: uncovering a central role of ERK activation.JAK2 抑制剂在 MPN 中的持续存在：揭示 ERK 激活的核心作用。
Blood Cancer J. 2022 Jan 26;12(1):13. doi: 10.1038/s41408-022-00609-5.
10
The Power of Extracellular Vesicles in Myeloproliferative Neoplasms: "Crafting" a Microenvironment That Matters.细胞外囊泡在骨髓增殖性肿瘤中的作用：“塑造”重要的微环境。
Cells. 2021 Sep 4;10(9):2316. doi: 10.3390/cells10092316.
本文引用的文献
1
Longitudinal Cytokine Profiling Identifies GRO-α and EGF as Potential Biomarkers of Disease Progression in Essential Thrombocythemia.纵向细胞因子分析确定GRO-α和表皮生长因子为原发性血小板增多症疾病进展的潜在生物标志物。
Hemasphere. 2020 May 21;4(3):e371. doi: 10.1097/HS9.0000000000000371. eCollection 2020 Jun.
2
Single-Cell Analyses Reveal Megakaryocyte-Biased Hematopoiesis in Myelofibrosis and Identify Mutant Clone-Specific Targets.单细胞分析揭示骨髓纤维化中巨核细胞偏向性造血并鉴定突变克隆特异性靶点。
Mol Cell. 2020 May 7;78(3):477-492.e8. doi: 10.1016/j.molcel.2020.04.008.
3
Myeloid PTEN promotes chemotherapy-induced NLRP3-inflammasome activation and antitumour immunity.髓系细胞 PTEN 促进化疗诱导的 NLRP3 炎性小体激活和抗肿瘤免疫。
Nat Cell Biol. 2020 Jun;22(6):716-727. doi: 10.1038/s41556-020-0510-3. Epub 2020 May 4.
4
Modifiable Lifestyle and Medical Risk Factors Associated With Myeloproliferative Neoplasms.与骨髓增殖性肿瘤相关的可改变生活方式及医学风险因素
Hemasphere. 2020 Jan 3;4(1):e327. doi: 10.1097/HS9.0000000000000327. eCollection 2020 Feb.
5
N-acetylcysteine inhibits thrombosis in a murine model of myeloproliferative neoplasm.N-乙酰半胱氨酸抑制骨髓增殖性肿瘤小鼠模型中的血栓形成。
Blood Adv. 2020 Jan 28;4(2):312-321. doi: 10.1182/bloodadvances.2019000967.
6
Somatic mutations and cell identity linked by Genotyping of Transcriptomes.通过转录组的基因分型将体细胞突变与细胞身份联系起来。
Nature. 2019 Jul;571(7765):355-360. doi: 10.1038/s41586-019-1367-0. Epub 2019 Jul 3.
7
Platelets as Mediators of Thromboinflammation in Chronic Myeloproliferative Neoplasms.血小板在慢性骨髓增殖性肿瘤中的血栓炎症中介作用。
Front Immunol. 2019 Jun 14;10:1373. doi: 10.3389/fimmu.2019.01373. eCollection 2019.
8
Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NFκB signaling.骨髓纤维化中的细胞因子产生表现出对 JAK-STAT、MAP 激酶和 NFκB 信号的不同反应性。
Leukemia. 2019 Aug;33(8):1978-1995. doi: 10.1038/s41375-019-0379-y. Epub 2019 Feb 4.
9
Defective negative regulation of Toll-like receptor signaling leads to excessive TNF-α in myeloproliferative neoplasm.Toll 样受体信号转导的缺陷负调控导致骨髓增殖性肿瘤中 TNF-α 过多。
Blood Adv. 2019 Jan 22;3(2):122-131. doi: 10.1182/bloodadvances.2018026450.
10
Smoking is associated with increased risk of myeloproliferative neoplasms: A general population-based cohort study.吸烟与骨髓增生性肿瘤风险增加相关：基于一般人群的队列研究。
Cancer Med. 2018 Nov;7(11):5796-5802. doi: 10.1002/cam4.1815. Epub 2018 Oct 14.
Zotero 插件